on NEOVACS (EPA:ALNEV)
Fundraising of €0.25 million by Néovacs
Neovacs (Euronext Growth Paris: ALNEV) announced on September 18, 2024 a fundraising of €0.25 million through the issuance of OCEANE-BSA. These convertible bonds were subscribed by European High Growth Opportunities Securitization Fund.
The net proceeds of €240,000 will fund the Kinoïde® allergy research program and strengthen investments in biotechnology and medical device projects. Prior to this round, €26.1 million had been raised, resulting in the creation of more than 23 billion shares.
This new issue could generate an additional 500 million shares, reducing a shareholder's stake from 1% to 0.46%. Neovacs warns of the risks of dilution for shareholders.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NEOVACS news